MedTrace Logo

Accelerating Referral for Thrombectomy in Acute Stroke Patients Using an Artificial Intelligence-based Software

NCT06741332 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2024-12-18

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if an AI-based imaging software, Methinks Stroke Suite, can reduce the time to transfer stroke patients who need thrombectomy from local stroke centers to specialized centers. The study focuses on acute stroke patients who are initially evaluated at local stroke centers that cannot perform endovascular therapy (EVT). The main questions it aims to answer are:

* Does Methinks Stroke Suite reduce the time it takes to decide if a patient needs to be transferred for thrombectomy?
* How accurate is the AI software in identifying patients who are candidates for EVT?

Researchers will compare the AI-based workflow to a historical cohort to see if the Methinks Stroke Suite improves transfer decisions and treatment times.

Participants will:

* Undergo a CT scan at the local stroke center, which will be analyzed by Methinks Stroke Suite.
* Be transferred to a thrombectomy-capable center if the AI + clinical judgment identifies them as potential EVT candidates.
* Be followed for 90 days after their stroke to assess recovery outcomes.

Conditions

  • Stroke
  • Stroke Acute
  • Ischemic Stroke, Acute
  • Thrombectomy

Interventions

DEVICE

Methinks software

Introduction in the stroke code workflow the Methinks AI software capable of detecting LVO on NCCT and CTA, and ICH on NCCT.

OTHER

Normal CT scans evaluation

The control group is obtained from a historical cohort at each participating center. We include consecutive suspected acute stroke patients who meet the same inclusion/exclusion criteria defined above, except for Methinks image processing.

Sponsors & Collaborators

  • Methinks Software SL

    collaborator INDUSTRY

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-27
Primary Completion
2026-01-31
Completion
2026-03-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06741332 on ClinicalTrials.gov